RESUMEN
Two groups of facts have been established in previous drug development studies of the non-benzodiazepine anxiolytic fabomotizole. First, fabomotizole prevents stress-induced decrease in binding ability of the GABAA receptor's benzodiazepine site. Second, fabomotizole is a Sigma1R chaperone agonist, and exposure to Sigma1R antagonists blocks its anxiolytic effect. To prove our main hypothesis of Sigma1R involvement in GABAA receptor-dependent pharmacological effects, we performed a series of experiments on BALB/c and ICR mice using Sigma1R ligands to study anxiolytic effects of benzodiazepine tranquilizers diazepam (1 mg/kg i.p.) and phenazepam (0.1 mg/kg i.p.) in the elevated plus maze test, the anticonvulsant effects of diazepam (1 mg/kg i.p.) in the pentylenetetrazole-induced seizure model, and the hypnotic effects of pentobarbital (50 mg/kg i.p.). Sigma1R antagonists BD-1047 (1, 10, and 20 mg/kg i.p.), NE-100 (1 and 3 mg/kg i.p.), and Sigma1R agonist PRE-084 (1, 5, and 20 mg/kg i.p.) were used in the experiments. Sigma1R antagonists have been found to attenuate while Sigma1R agonists can enhance GABAARs-dependent pharmacological effects.
Asunto(s)
Ansiolíticos , Receptores de GABA-A , Animales , Ratones , Ansiolíticos/farmacología , Anticonvulsivantes/farmacología , Benzodiazepinas/farmacología , Diazepam/farmacología , Hipnóticos y Sedantes/farmacología , Ligandos , Ratones Endogámicos ICR , Receptores de GABA-A/metabolismo , Informe de Investigación , Receptor Sigma-1RESUMEN
Modern pharmacotherapy of neurodegenerative diseases is predominantly symptomatic and does not allow vicious circles causing disease development to break. Protein misfolding is considered the most important pathogenetic factor of neurodegenerative diseases. Physiological mechanisms related to the function of chaperones, which contribute to the restoration of native conformation of functionally important proteins, evolved evolutionarily. These mechanisms can be considered promising for pharmacological regulation. Therefore, the aim of this review was to analyze the mechanisms of endoplasmic reticulum stress (ER stress) and unfolded protein response (UPR) in the pathogenesis of neurodegenerative diseases. Data on BiP and Sigma1R chaperones in clinical and experimental studies of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease are presented. The possibility of neuroprotective effect dependent on Sigma1R ligand activation in these diseases is also demonstrated. The interaction between Sigma1R and BiP-associated signaling in the neuroprotection is discussed. The performed analysis suggests the feasibility of pharmacological regulation of chaperone function, possibility of ligand activation of Sigma1R in order to achieve a neuroprotective effect, and the need for further studies of the conjugation of cellular mechanisms controlled by Sigma1R and BiP chaperones.
Asunto(s)
Enfermedades Neurodegenerativas , Fármacos Neuroprotectores , Humanos , Neuroprotección , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Ligandos , Chaperonas Moleculares/metabolismo , Respuesta de Proteína Desplegada , Estrés del Retículo Endoplásmico , Enfermedades Neurodegenerativas/tratamiento farmacológicoRESUMEN
Induction of BDNF-TrkB signaling is associated with the action mechanisms of conventional and fast-acting antidepressants. GSB-106, developed as a small dimeric dipeptide mimetic of BDNF, was previously shown to produce antidepressant-like effects in the mouse Porsolt test, tail suspension test, Nomura water wheel test, in the chronic social defeat stress model and in the inflammation-induced model of depression. In the present study, we evaluated the effect of chronic per os administration of GSB-106 to Balb/c mice under unpredictable chronic mild stress (UCMS). It was observed for the first time that long term GSB-106 treatment (1 mg/kg, 26 days) during ongoing UCMS procedure ameliorated the depressive-like behaviors in mice as indicated by the Porsolt test. In addition, chronic per os administration of GSB-106 resulted in an increase in BDNF levels, which were found to be decreased in the prefrontal cortex and hippocampus of mice after UCMS. Furthermore, prolonged GSB-106 treatment was accompanied by an increase in the content of pTrkB706/707 in the prefrontal cortex and by a pronounced increase in the level of pTrkB816 in both studied brain structures of mice subjected to UCMS procedure. In summary, the present data show that chronic GSB-106 treatment produces an antidepressant-like effect in the unpredictable chronic mild stress model, which is likely to be associated with the regulation of the BDNF-TrkB signaling.
Asunto(s)
Dipéptidos/metabolismo , Dipéptidos/farmacología , Glicoproteínas de Membrana/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Animales , Antidepresivos/farmacología , Encéfalo/metabolismo , Factor Neurotrófico Derivado del Encéfalo/efectos de los fármacos , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Masculino , Glicoproteínas de Membrana/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/metabolismo , Proteínas Tirosina Quinasas/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Estrés PsicológicoRESUMEN
The ability of NQO2 to increase the production of free radicals under enhanced generation of quinone derivatives of catecholamines is considered to be a component of neurodegenerative disease pathogenesis. The present study aimed to investigate the neuroprotective mechanisms of original NQO2 inhibitor M-11 (2-[2-(3-oxomorpholin-4-il)-ethylthio]-5-ethoxybenzimidazole hydrochloride) in a cellular damage model using NQO2 endogenous substrate adrenochrome (125 µM) and co-substrate BNAH (100 µM). The effects of M-11 (10-100 µM) on the reactive oxygen species (ROS) generation, apoptosis and lesion of nuclear DNA were evaluated using flow cytometry and single-cell gel electrophoresis assay (comet assay). Results were compared with S29434, the reference inhibitor of NQO2. It was found that treatment of HT-22 cells with M-11 results in a decline of ROS production triggered by incubation of cells with NQO2 substrate and co-substrate. Pre-incubation of HT-22 cells with compounds M-11 or S29434 results in a decrease of DNA damage and late apoptotic cell percentage reduction. The obtained results provide a rationale for further development of the M-11 compound as a potential neuroprotective agent.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Quinona Reductasas/antagonistas & inhibidores , Adrenocromo/metabolismo , Animales , Apoptosis/efectos de los fármacos , Bencimidazoles/química , Línea Celular , Daño del ADN , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/química , Hipocampo/citología , Masculino , Ratones Endogámicos ICR , Neuronas/metabolismo , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/química , Piridinas/farmacología , Alcaloides de Pirrolicidina/farmacología , Quinona Reductasas/metabolismo , Especies Reactivas de Oxígeno/metabolismoRESUMEN
Sigma-1 receptor (chaperone Sigma1R) is an intracellular protein with chaperone functions, which is expressed in various organs, including the brain. Sigma1R participates in the regulation of physiological mechanisms of anxiety (Su, T. P. et al., 2016) and reactions to emotional stress (Hayashi, T., 2015). In 2006, fabomotizole (ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride) was registered in Russia as an anxiolytic (Seredenin S. and Voronin M., 2009). The molecular targets of fabomotizole are Sigma1R, NRH: quinone reductase 2 (NQO2), and monoamine oxidase A (MAO-A) (Seredenin S. and Voronin M., 2009). The current study aimed to clarify the dependence of fabomotizole anxiolytic action on its interaction with Sigma1R and perform a docking analysis of fabomotizole interaction with Sigma1R. An elevated plus maze (EPM) test revealed that the anxiolytic-like effect of fabomotizole (2.5 mg/kg i.p.) administered to male BALB/c mice 30 min prior EPM exposition was blocked by Sigma1R antagonists BD-1047 (1.0 mg/kg i.p.) and NE-100 (1.0 mg/kg i.p.) pretreatment. Results of initial in silico study showed that fabomotizole locates in the active center of Sigma1R, reproducing the interactions with the site's amino acids common for established Sigma1R ligands, with the ΔGbind value closer to that of agonist (+)-pentazocine in the 6DK1 binding site.
Asunto(s)
Ansiolíticos/farmacología , Ansiedad/tratamiento farmacológico , Bencimidazoles/farmacología , Chaperonas Moleculares/metabolismo , Morfolinas/farmacología , Receptores sigma/metabolismo , Animales , Anisoles/farmacología , Sitios de Unión/fisiología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Etilenodiaminas/farmacología , Ligandos , Masculino , Ratones , Ratones Endogámicos BALB C , Propilaminas/farmacología , Federación de Rusia , Receptor Sigma-1RESUMEN
This review provides the results of many years of original studies of the authors published in different journals and compilations taking into account an analysis of literature data. The studies on biological diversity of lung helminths of terrestrial mammals were performed by the authors in Armenia, Bulgaria and Poland. Literature data on European Russia were also taken into account. Sixteen animal species from the families Cervidae (six species), Bovidae (nine species) and Leporidae (one species) were investigated. In these animal taxons 27 helminth species from the families Dictyocaulidae (five species), Protostrongylidae (20 species), and Taeniidae (two species) have been found. Lung nematodes Muellerius capillaris and Protostrongylus hobmaieri, as well as zoonotic parasite E. granulosus were found to be common for all the countries studied. Also, relatively many species appeared common between several studied regions. Taking into account morphology, ecology and life cycles, we support a validity of genera Echinococcus and Alveococcus in the structure of the subfamily Echinococcinae of family Taeniidae.
Asunto(s)
Ciervos , Helmintiasis Animal , Helmintos , Metastrongyloidea , Animales , Biodiversidad , Helmintiasis Animal/parasitología , Humanos , Pulmón , Polonia/epidemiologíaRESUMEN
Previously, we demonstrated that the immediate administration of multitarget anxiolytic afobazole slows down the progression of neuronal damage in a 6-hydroxidodamine (6-OHDA) model of Parkinson's disease due to the activation of chaperone Sigma1R. The aim of the present study is to evaluate the therapeutic potential of deferred afobazole administration in this model. Male ICR mice received a unilateral 6-OHDA lesion of the striatum. Fourteen days after the surgery, mice were treated with afobazole, selective Sigma1R agonist PRE-084, selective Sigma1R antagonist BD-1047, and a combination of BD-1047 with afobazole or PRE-084 for another 14 days. The deferred administration of afobazole restored the intrastriatal dopamine content in the 6-OHDA-lesioned striatum and facilitated motor behavior in rotarod tests. The action of afobazole accorded with the effect of Sigma1R selective agonist PRE-084 and was blocked by Sigma1R selective antagonist BD-1047. The present study illustrates the Sigma1R-dependent effects of afobazole in a 6-OHDA model of Parkinson's disease and reveals the therapeutic potential of Sigma1R agonists in treatment of the condition.
Asunto(s)
Bencimidazoles/uso terapéutico , Cuerpo Estriado/metabolismo , Dopamina/metabolismo , Morfolinas/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Receptores sigma/metabolismo , Animales , Bencimidazoles/administración & dosificación , Bencimidazoles/farmacología , Cuerpo Estriado/efectos de los fármacos , Etilenodiaminas/farmacología , Masculino , Ratones , Ratones Endogámicos ICR , Morfolinas/administración & dosificación , Morfolinas/farmacología , Movimiento , Receptores sigma/agonistas , Receptores sigma/antagonistas & inhibidores , Receptor Sigma-1RESUMEN
This review analyzes the current scientific literature on the role of the Sigma1R chaperone in the pathogenesis of depressive disorders and pharmacodynamics of antidepressants. As a result of ligand activation, Sigma1R is capable of intracellular translocation from the endoplasmic reticulum (ER) into the region of nuclear and cellular membranes, where it interacts with resident proteins. This unique property of Sigma1R provides regulation of various receptors, ion channels, enzymes, and transcriptional factors. The current review demonstrates the contribution of the Sigma1R chaperone to the regulation of molecular mechanisms involved in the antidepressant effect.
Asunto(s)
Antidepresivos , Trastorno Depresivo , Receptores sigma/fisiología , Animales , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Trastorno Depresivo/metabolismo , Humanos , Receptor Sigma-1RESUMEN
Parkinson's disease (PD) is a progressive neurodegenerative disease with limited treatment options. Therefore, the identification of therapeutic targets is urgently needed. Previous studies have shown that the ligand activation of the sigma-1 chaperone (Sigma1R) promotes neuroprotection. The multitarget drug afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride) was shown to interact with Sigma1Rs and prevent decreases in striatal dopamine in the 6-hydroxydopamine (6-OHDA)-induced parkinsonism model. The aim of the present study was to elucidate the role of Sigma1Rs in afobazole pharmacological activity. Using ICR mice we found that administration of afobazole (2.5 mg/kg, i.p.) or selective agonist of Sigma1R PRE-084 (1.0 mg/kg, i.p.) over 14 days normalizes motor disfunction and prevents decreases in dopamine in the 6-OHDA-lesioned striatum. Afobazole administration also prevents the loss of TH + neurons in the substantia nigra. The pre-administration of selective Sigma1R antagonist BD-1047 (3.0 mg/kg, i.p.) abolishes the activity of either afobazole or PRE-084, as determined using the rotarod test and the analysis of striatal dopamine content. The current study demonstrates the contribution of Sigma1Rs in the neuroprotective effect of afobazole in the 6-OHDA model of Parkinson's disease and defines the therapeutic perspective of Sigma1R agonists in the clinic.
Asunto(s)
Bencimidazoles/farmacología , Morfolinas/farmacología , Neuroprotección/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Enfermedad de Parkinson/tratamiento farmacológico , Receptores sigma/metabolismo , Animales , Cuerpo Estriado/efectos de los fármacos , Modelos Animales de Enfermedad , Dopamina/metabolismo , Etilenodiaminas/farmacología , Masculino , Ratones , Ratones Endogámicos ICR , Neuronas/efectos de los fármacos , Oxidopamina , Enfermedad de Parkinson/fisiopatología , Receptores sigma/agonistas , Receptores sigma/antagonistas & inhibidores , Prueba de Desempeño de Rotación con Aceleración Constante , Sustancia Negra/citología , Sustancia Negra/efectos de los fármacos , Receptor Sigma-1RESUMEN
The review provides data on species composition of nematode parasites of cattle, sheep, goats and wild ruminants (Ovis orientalis gmelini, Capreolus capreolus, Capra aegagrus aegagrus) of Armenia. Six species of lung nematodes and 22 species of gastrointestinal ones have been registered in ruminants of Armenia. Five of the species listed in the review (Protostrongylus davtiani, Protostrongylus muraschkinzewi, Nematodirus davtiani, Trichostrongylus andreevi, Trichostrongylus skrjabini) have been first identified in Armenia. The ruminant host species most studied for this territory is a domestic sheep. Data on nematodes of goats and wild ruminants are limited to sporadic reports. Data on nematodes of cattle are limited to the only one species Neoascaris vitulorum. Most of the nematode species found in Armenia are common for all ruminant host species living here and noted as widespread all over the world. Eight species of nematodes detected in ruminants of Armenia able to infect humans. The taxonomy of some rare species of nematodes reported from ruminants in Armenia is not entirely clear and should be re-evaluated basing on thorough studies.
Asunto(s)
Biodiversidad , Nematodos , Infecciones por Nematodos , Rumiantes , Animales , Animales Domésticos/parasitología , Animales Salvajes/parasitología , Armenia , Nematodos/clasificación , Infecciones por Nematodos/parasitología , Infecciones por Nematodos/veterinaria , Rumiantes/parasitologíaRESUMEN
Anxiolytic afobazole (5-Ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihidrochloride) has pronounced ligand properties toward Sigma-1 receptor (σ1 receptor,SigmaR1) and MT 3 receptors. Our previous work demonstrated that afobazole possess cytoprotective effect in the in vitro model of menadione genotoxicity (Woods et al. 1997) through interaction with MT 3 receptor (Kadnikov et al. 2014). Present study utilized previously described models to address the contribution of SigmaR1 to cytoprotective action of afobazole. The reduction in afobazole cytoprotective effect observed after preincubation of cell suspension with selective SigmaR1 antagonist BD-1047 revealed an important contribution of SigmaR1 in afobazole-mediated effect. We confirmed our observation using selective SigmaR1 agonist PRE-084. We conclude that pronounced cytoprotective effect of afobazole over PRE-084 is likely achieved by additive SigmaR1 and MT 3-mediated effects.